The cellular immunotherapy of cancer: Current and potential uses of interleukin-2
- 31 December 1989
- journal article
- clinical trial
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 9 (2) , 125-147
- https://doi.org/10.1016/s1040-8428(89)80008-3
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Clonal analysis of the cytolytic T-cell response to human tumorsImmunology Today, 1987
- T Lymphocytes: Ontogeny, Function, and Relevance to Clinical DisordersNew England Journal of Medicine, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Allele-specific alien-driven diversity, immune responsiveness and MHC-restrictionImmunology Today, 1985
- The proliferative immune response to autologous Epstein-Barr virus-transformed lymphoblastoid cells. I. Studies with HLA haplotype loss variants demonstrate a role for MHC-linked genesHuman Immunology, 1985
- Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigensHuman Immunology, 1984
- Antileukemic Effect of Chronic Graft-versus-Host DiseaseNew England Journal of Medicine, 1981
- Associations Between Major Histocompatibility Antigens and Susceptibility to DiseaseAnnual Review of Microbiology, 1979